Franklin Street Advisors Inc. NC Has $1.22 Million Holdings in Pfizer Inc. (NYSE:PFE)

Franklin Street Advisors Inc. NC reduced its stake in Pfizer Inc. (NYSE:PFE) by 1.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,944 shares of the biopharmaceutical company’s stock after selling 518 shares during the period. Franklin Street Advisors Inc. NC’s holdings in Pfizer were worth $1,219,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Mather Group LLC. boosted its holdings in shares of Pfizer by 35.0% during the third quarter. Mather Group LLC. now owns 34,169 shares of the biopharmaceutical company’s stock worth $1,133,000 after acquiring an additional 8,857 shares during the period. Weik Capital Management boosted its stake in Pfizer by 1.0% in the 3rd quarter. Weik Capital Management now owns 41,154 shares of the biopharmaceutical company’s stock valued at $1,365,000 after purchasing an additional 400 shares during the period. Valley National Advisers Inc. boosted its stake in Pfizer by 2.5% in the 3rd quarter. Valley National Advisers Inc. now owns 31,751 shares of the biopharmaceutical company’s stock valued at $1,053,000 after purchasing an additional 782 shares during the period. Treasurer of the State of North Carolina grew its holdings in Pfizer by 1.1% in the 3rd quarter. Treasurer of the State of North Carolina now owns 2,775,199 shares of the biopharmaceutical company’s stock valued at $92,053,000 after buying an additional 31,399 shares in the last quarter. Finally, Sandhill Capital Partners LLC increased its position in Pfizer by 6.4% during the 3rd quarter. Sandhill Capital Partners LLC now owns 107,633 shares of the biopharmaceutical company’s stock worth $3,570,000 after buying an additional 6,455 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 1.1 %

PFE traded up $0.30 during trading on Thursday, hitting $27.72. The company’s stock had a trading volume of 18,200,402 shares, compared to its average volume of 40,888,766. The firm has a market capitalization of $157.08 billion, a P/E ratio of -458.26, a PEG ratio of 1.10 and a beta of 0.70. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The stock’s fifty day moving average price is $27.81 and its 200-day moving average price is $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s revenue was down 19.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.23 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.06%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on PFE shares. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Morgan Stanley increased their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.